Metformin for Antipsychotic-Related Weight Gain and Metabolic Abnormalities: When, for Whom, and for How Long?
2013; American Psychiatric Association; Volume: 170; Issue: 9 Linguagem: Inglês
10.1176/appi.ajp.2013.13060771
ISSN1535-7228
AutoresChristoph U. Correll, Linmarie Sikich, Gloria Reeves, Mark A. Riddle,
Tópico(s)Schizophrenia research and treatment
ResumoBack to table of contents Previous article Next article PerspectivesFull AccessMetformin for Antipsychotic-Related Weight Gain and Metabolic Abnormalities: When, for Whom, and for How Long?Christoph U. Correll, M.D., Linmarie Sikich, M.D., Gloria Reeves, M.D., and Mark Riddle, M.D.Christoph U. Correll, M.D., Linmarie Sikich, M.D., Gloria Reeves, M.D., and Mark Riddle, M.D.Published Online:1 Sep 2013https://doi.org/10.1176/appi.ajp.2013.13060771AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinked InEmail The seriously mentally ill have significantly more cardiovascular risk factors, receive less appropriate medical care, and die on average 15 to 30 years earlier than the general population, mostly because of cardiovascular disorders (1). Reasons for this physical health disparity are complex and include unhealthy lifestyle behaviors, illness-related effects (including poverty, negative symptoms, depression, etc.), unclear genetic links between mental and medical disorders, and adverse medication effects, particularly of antipsychotics (1). Antipsychotics are key to managing schizophrenia spectrum disorders (2) and are prescribed for various other psychiatric conditions (3). However, their benefit-to-risk ratio is challenged by weight gain and metabolic abnormalities (1). Several strategies help minimize adverse cardiometabolic effects of antipsychotics: healthy lifestyle interventions (4), switching to lower-risk antipsychotics (5), and the addition of medications that may lower body weight and/or lipid and glucose parameters (6). Interestingly, each of these strategies reduces body weight to a similar, relatively limited extent of roughly 3 kg over 3 to 6 months (4–6).Among pharmacologic interventions, metformin, which is indicated for the treatment of diabetes in those 10 years and older, has been studied the most (6–9). In contrast to several weight-loss agents that have been removed from the market because of potentially serious adverse events, metformin has a well-established safety profile in both adults and youths. The most frequent side effects are nausea, vomiting, and diarrhea. Lactic acidosis is extremely rare, especially in nonelderly populations and in those with creatinine levels <1.4. The potential risk of neuropathy as a result of chronic vitamin malabsorption is easily minimized by daily multivitamin supplementation. However, previous metformin studies targeting antipsychotic-induced weight gain have generally been small (32 to 84 participants, median=55) (6–12), leading to relatively wide confidence intervals (Figure 1) and precluding mediator and moderator analyses.FIGURE 1. Randomized Controlled Trials Comparing Metformin With Placeboa Data represent the mean difference in body weight (kg), using the inverse variance statistical method in a random-effects model.b Metformin was concurrently started with antipsychotic treatment.c Metformin was added to ongoing antipsychotic treatment that caused weight gain.In this issue of the Journal, the study by Jarskog et al. (13) is the largest study to date of metformin in antipsychotic-treated patients (N=146). It compared 16 weeks of 1,000 mg of metformin twice daily (mean final dose=1,887 mg [SD=292]) with placebo in antipsychotic-treated adults. Additionally, all participants received a standardized healthy lifestyle intervention, deliverable in usual care settings. Generalizability was enhanced by including patients with a body mass index (BMI) ≥27 (mean=34.6 [SD=5.9]) independent of timing and amount of prior weight gain, different levels of chronicity of psychosis, comorbid psychiatric conditions, and treatment with two antipsychotics or psychiatric comedications, excluding only diabetic individuals. Furthermore, for the first time, exploratory moderator and mediator analyses of metformin's efficacy were performed. Metformin was associated with a −3.0-kg weight loss (95% confidence interval [CI]=−4.0 to −2.0) that was significantly greater than the small weight reduction of −1.0 kg (95% CI=−2.0 to 0.0) in the placebo group. This weight reduction translated into a −0.7 (95% CI=−1.1 to −0.2) greater BMI reduction compared with placebo. However, the mean percent weight loss was only 2.8% of baseline weight with metformin compared with 1.0% with placebo, and only 17.3% and 9.8% of participants, respectively, lost ≥5% of their baseline body weight. A linear time-by-treatment interaction suggests that weight loss could possibly continue beyond 16 weeks. Additionally, the fact that the placebo group lost 1 kg over 4 months suggests that healthy lifestyle intervention can reduce some weight in motivated patients, like those participating in research. Metformin was also associated with significantly lower triglyceride and hemoglobin A1C levels than placebo. The latter findings indicate that the weight reduction with metformin was associated with important additional benefits regarding lipid and glucose metabolism, which are closely related to the risk for diabetes and cardiovascular disease (1). Notably, metformin was well tolerated. Furthermore, younger age (<44 years old), lower BMI (<33), male sex, and nonsmoking status were associated with greater weight loss with metformin. The authors noted the inadequate power for these post hoc analyses, which likely contributed to the failure to discern significant benefits in women, who comprised only 30% of the study sample.From this (13) and 10 other published studies (7–12, 14–17) comparing metformin with placebo in 685 antipsychotic-treated patients over a mean of 15.5 weeks, we can conclude that 1) metformin significantly reduces body weight; 2) weight loss is statistically and clinically significant but relatively modest (−3.1 kg; 95% CI=−4.5 to −1.6 [Figure 1]); 3) despite the relatively modest weight loss, significant benefits are observed for at least some lipid and glucose parameters; 4) metformin is well tolerated; and 5) weight seems to be regained after stopping metformin (9). However, weight loss was highly heterogeneous (p<0.00001). Weight reduction appears most pronounced in first-episode studies (8, 10). Moreover, it is unclear whether there is a difference between metformin's efficacy in prevention studies, in which metformin was started at the same time as the antipsychotics, and intervention studies, in which metformin was added to a stable antipsychotic regimen after significant weight gain occurred. Although weight loss with these two intervention strategies was similar, two of the three prevention trials, conducted in Chinese first-episode patients (8, 10), had among the most favorable outcomes, whereas the third trial, conducted in South America (12), showed no benefit. Thus, it remains unclear to what extent these findings reflect moderating effects of age, illness/treatment phase, or ethnicity versus inherent differences in prevention versus intervention approaches.Similarly, a meta-analysis of 17 controlled trials (N=810) of healthy lifestyle intervention in antipsychotic-treated adults confirmed superior weight loss with healthy lifestyle intervention after a mean of 19.6 weeks (−3.1 kg; 95% CI=−4.4 to −1.7), with similar effects for prevention and intervention studies (4). On average, 3.6 months after stopping the healthy lifestyle intervention, benefits endured regarding weight but not BMI. In a recent, large study not included in that meta-analysis, only 3.2 kg (95% CI=−5.1 to −1.2) were lost at 18 months in 279 patients with mixed psychiatric disorders receiving tailored group or individual healthy lifestyle intervention compared with nutrition/exercise information, followed by monthly health classes (18). Interestingly, in this unique, long-term study, participants continued to demonstrate progressive weight loss throughout the 18-month study period in contrast to studies of nonpsychiatric populations in which weight loss generally plateaus after 6 months. The authors speculated that it may take individuals with serious mental illness longer to fully engage in healthy lifestyle intervention.Only one trial has compared metformin alone, placebo plus healthy lifestyle intervention, and metformin plus healthy lifestyle intervention (11). In that study, significant advantages for reducing body weight and improving glucose- and insulin-related outcomes were observed for combined metformin plus healthy lifestyle intervention compared with either healthy lifestyle intervention alone or metformin alone. It is unclear whether the limited benefit of healthy lifestyle intervention in this study reflects the relatively short duration of the study or the limited engagement of severely ill patients in healthy lifestyle intervention (12). Such comparisons warrant further study, especially since in the general population, studied in the Diabetes Prevention Program (19), the opposite appears to be true, in that healthy lifestyle intervention was superior to metformin. Moreover, it is concerning that no healthy lifestyle intervention study (4) and only two small metformin studies (14, 17) have been conducted in antipsychotic-treated youths, a population increasingly receiving antipsychotics (3) and particularly vulnerable to antipsychotic-related cardiometabolic effects (1). Importantly, the relative efficacy and effectiveness of adding metformin versus switching to antipsychotics with lower weight gain potential, which has been shown to be effective (5), is another pressing question. Some of these gaps are being addressed in an ongoing National Institute of Mental Health-funded study of youths between 8 and 19 years old with psychotic, mood, and autism spectrum disorders who gained clinically significant weight on antipsychotics. For the first time, addition of metformin plus healthy lifestyle intervention, switch to a lower-risk antipsychotic plus healthy lifestyle intervention, and healthy lifestyle intervention alone will be directly compared (http://clinicaltrials.gov/show/NCT00806234). Findings are expected in 2014.In summary, metformin augmentation of antipsychotics is an evidence-based option to reduce antipsychotic-associated cardiometabolic effects. However, the overall weight loss is modest compared with the weight generally gained on antipsychotics (1, 4, 6), and metformin should likely only be added after a clinical trial of a psychosocial intervention for weight loss has proven to be ineffective. Such interventions include psychoeducation focused on nutritional counseling, caloric expenditure, and portion control; behavioral self-management including motivational enhancement; goal setting; regular weigh-ins; self-monitoring of daily food and activity levels; and dietary and physical activity modifications (20). More placebo-controlled trials of metformin, at least in adults, are not likely to advance our knowledge regarding strategies to control antipsychotic-associated weight gain, unless they last at least 6 months, are sufficiently large to identify mediators and moderators, and/or have a discontinuation phase. Conversely, studying metformin in comparison to or combined with other strategies is much needed. Additional comparators may include antipsychotic switching, topiramate, which is the second most effective medication for antipsychotic-related weight gain (6), or metformin plus topiramate in patients insufficiently benefiting from metformin. Furthermore, the two recently approved antiobesity medications, lorcarserin and phentermine plus topiramate-extended release, should not only be compared with placebo but also with metformin in antipsychotic-treated patients. Finally, not all antipsychotic-treated patients benefit sufficiently from metformin. It is essential to identify the best candidates for metformin. Future studies should ideally include patients with different durations of illness and ethnicities, stratifying randomization by first- versus multiepisode schizophrenia and Asian compared with non-Asian race, so that these moderators can be assessed. Similarly, a study comparing prevention versus intervention approaches would be informative. It is hoped that future studies will help clinicians make individualized management decisions for antipsychotic-treated patients that maximize psychiatric benefits while minimizing adverse health consequences.From the Department of Psychiatry Research, Zucker Hillside Hospital, North Shore-Long Island Jewish Health System, Glen Oaks, N.Y.; Hofstra North Shore-Long Island Jewish School of Medicine, Hempstead, N.Y.; the Feinstein Institute for Medical Research, Manhasset, N.Y.; University of North Carolina at Chapel Hill, Chapel Hill, N.C.; University of Maryland School of Medicine, Baltimore; and Johns Hopkins University School of Medicine, Baltimore.Address correspondence to Dr. Correll ([email protected]edu).Funded in part by NIMH grant 1R01MH080274-01A2 (principal investigator, Dr. Riddle), the University of North Carolina (principal investigator, Dr. Sikich), and North Shore-Long Island Jewish Medical Center (principal investigator, Dr. Correll).Dr. Correll has served as a consultant and/or advisor to and has received honoraria from Actelion, Alexza, the American Academy of Child and Adolescent Psychiatry, Bristol-Myers Squibb, Cephalon, Eli Lilly, Genentech, Gerson Lehrman Group, IntraCellular Therapies, Lundbeck, Medavante, Medscape, Merck, NIMH, Janssen/Johnson and Johnson, Otsuka, Pfizer, ProPhase, Roche, Sunovion, Takeda, Teva, and Vanda; and he has received grant support and/or donation of medication from Bristol-Myers Squibb, the Feinstein Institute for Medical Research, Janssen/Johnson and Johnson, and NIMH. Dr. Sikich has received research grant support from or has participated in clinical trials sponsored by Autism Speaks, Bristol-Myers Squibb, Curemark, Forest, Foundation of Hope, Merck, NIMH, Otsuka Research Institute, Seaside Pharmaceuticals, Sunovion, and SynapDx; she has served as a consultant to ABT Associates and Sanofi-Aventis and has received software for a computer intervention in schizophrenia from Posit Science; she also serves on the data safety and monitoring boards for the National Institute of Child Health and Human Development Rare Diseases Network and the Research Foundation for Mental Hygiene. Dr. Riddle has received research grant support from NIMH and a donation of medication from Bristol-Myers Squibb and serves on the data safety and monitoring boards for the Best Pharmaceuticals for Children Act. Dr. Reeves has received research grant support from NIMH and a donation of medication from Bristol-Myers Squibb. Dr. Freedman has reviewed this editorial and found no evidence of influence from these relationships.References1 De Hert M, Detraux J, van Winkel R, Yu W, Correll CU: Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2012; 8:114–126Crossref, Google Scholar2 Kane JM, Correll CU: Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry 2010; 71:1115–1124Crossref, Medline, Google Scholar3 Olfson M, Blanco C, Liu SM, Wang S, Correll CU: National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry 2012; 69:1247–1256Crossref, Medline, Google Scholar4 Caemmerer J, Correll CU, Maayan L: Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials. Schizophr Res 2012; 140:159–168Crossref, Medline, Google Scholar5 Stroup TS, McEvoy JP, Ring KD, Hamer RH, LaVange LM, Swartz MS, Rosenheck RA, Perkins DO, Nussbaum AM, Lieberman JA; Schizophrenia Trials Network: A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: Comparison of Antipsychotics for Metabolic Problems (CAMP). Am J Psychiatry 2011; 168:947–956Link, Google Scholar6 Maayan L, Vakhrusheva J, Correll CU: Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology 2010; 35:1520–1530Crossref, Medline, Google Scholar7 Wu RR, Jin H, Gao K, Twamley EW, Ou JJ, Shao P, Wang J, Guo XF, Davis JM, Chan PK, Zhao JP: Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study. Am J Psychiatry 2012; 169:813–821Link, Google Scholar8 Wang M, Tong JH, Zhu G, Liang GM, Yan HF, Wang XZ: Metformin for treatment of antipsychotic-induced weight gain: a randomized, placebo-controlled study. Schizophr Res 2012; 138:54–57Crossref, Medline, Google Scholar9 Chen CH, Huang MC, Kao CF, Lin SK, Kuo PH, Chiu CC, Lu ML: Effects of adjunctive metformin on metabolic traits in non-diabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2013; 74:e424–e430Google Scholar10 Wu RR, Zhao JP, Guo XF, He YQ, Fang MS, Guo WB, Chen JD, Li LH: Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. Am J Psychiatry 2008; 165:352–358Link, Google Scholar11 Wu RR, Zhao JP, Jin H, Shao P, Fang MS, Guo XF, He YQ, Liu YJ, Chen JD, Li LH: Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA 2008; 299:185–193Crossref, Medline, Google Scholar12 Baptista T, Martínez J, Lacruz A, Rangel N, Beaulieu S, Serrano A, Arapé Y, Martinez M, de Mendoza S, Teneud L, Hernández L: Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. Can J Psychiatry 2006; 51:192–196Crossref, Medline, Google Scholar13 Jarskog LF, Hamer RM, Catellier DJ, Stewart DD, LaVange L, Ray N, Golden LH, Lieberman JA, Stroup TS; for the METS Investigators: Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry 2013; 170:1032–1040Link, Google Scholar14 Arman S, Sadramely MR, Nadi M, Koleini N: A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents. Saudi Med J 2008; 29:1130–1134Medline, Google Scholar15 Baptista T, Rangel N, Fernandez V, Carrizo E, El Fakih Y, Uzcategui E, Galeazzi T, Gutiérrez MA, Servigna M, Dávila A, Uzcátegui M, Serrano A, Connell L, Beaulieu S, de Baptista EA: Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric,double-blind, placebo-controlled trial. Schizophr Res 2007; 93:99–108Crossref, Medline, Google Scholar16 Carrizo E, Fernández V, Connell L, Sandia I, Prieto D, Mogollón J, Valbuena D, Fernández I, de Baptista EA, Baptista T: Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study. Schizophr Res 2009; 113:19–26Crossref, Medline, Google Scholar17 Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA: A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry 2006; 163:2072–2079Link, Google Scholar18 Daumit GL, Dickerson FB, Wang NY, Dalcin A, Jerome GJ, Anderson CA, Young DR, Frick KD, Yu A, Gennusa JV, Oefinger M, Crum RM, Charleston J, Casagrande SS, Guallar E, Goldberg RW, Campbell LM, Appel LJ: A behavioral weight-loss intervention in persons with serious mental illness. N Engl J Med 2013; 368:1594–1602Crossref, Medline, Google Scholar19 Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM: Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393–403Crossref, Medline, Google Scholar20 Dixon LB, Dickerson F, Bellack AS, Bennett M, Dickinson D, Goldberg RW, Lehman A, Tenhula WN, Calmes C, Pasillas RM, Peer J, Kreyenbuhl J: Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements. Schizophr Bull 2010 Jan; 36:48–70Crossref, Google Scholar FiguresReferencesCited byDetailsCited byMetformin for Overweight and Obese Children With Bipolar Spectrum Disorders Treated With Second-Generation Antipsychotics (MOBILITY): Protocol and Methodological Considerations for a Large Pragmatic Randomized Clinical TrialJAACAP Open, Vol. 1, No. 1Pharmacological interventions for prevention of weight gain in people with schizophrenia3 October 2022 | Cochrane Database of Systematic Reviews, Vol. 2023, No. 1A single-blind, randomised controlled trial of a physical health nurse intervention to prevent weight gain and metabolic complications in first-episode psychosis: the Physical Health Assistance in Early Psychosis (PHAstER) study18 October 2022 | BJPsych Open, Vol. 8, No. 6Isolating the impact of antipsychotic medication on metabolic health: Secondary analysis of a randomized controlled trial of antipsychotic medication versus placebo in antipsychotic medication naïve first‐episode psychosis (the STAGES study)4 October 2022 | Early Intervention in Psychiatry, Vol. 10Twenty-Four Week, Randomized, Double-Blind, Placebo-Controlled Trial of Metformin for Antipsychotic-Induced Weight Gain in Patients with First-Episode Psychosis: A Pilot Study23 December 2021 | International Journal of Environmental Research and Public Health, Vol. 19, No. 1The need for early intervention for psychosis to persist throughout the COVID-19 pandemic and beyond21 May 2020 | Irish Journal of Psychological Medicine, Vol. 38, No. 3Metformin add‐on vs. antipsychotic switch vs. continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness: results from the IMPACT trial10 January 2020 | World Psychiatry, Vol. 19, No. 1Cardiometabolic Adverse Effects and Its Predictors in Children and Adolescents With First-Episode Psychosis During Treatment With Quetiapine-Extended Release Versus Aripiprazole: 12-Week Results From the Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis (TEA) TrialJournal of the American Academy of Child & Adolescent Psychiatry, Vol. 58, No. 11Health benefits of a physical exercise program for inpatients with mental health; a pilot studyJournal of Psychiatric Research, Vol. 113Mobility for All?Journal of the American Academy of Child & Adolescent Psychiatry, Vol. 57, No. 10Current Treatment Options in Psychiatry, Vol. 5, No. 4Perspectives in Psychiatric Care, Vol. 54, No. 4Effect of adjunctive ranitidine for antipsychotic-induced weight gain: A systematic review of randomized placebo-controlled trials18 July 2017 | Journal of International Medical Research, Vol. 46, No. 1Psychopharmacology, Vol. 234, No. 22Journal of Autism and Developmental Disorders, Vol. 47, No. 7Pharmacological Research, Vol. 117Frontiers in Psychiatry, Vol. 8Efficacy and safety of adjunctive topiramate for schizophrenia: a meta-analysis of randomized controlled trials1 September 2016 | Acta Psychiatrica Scandinavica, Vol. 134, No. 5Metformin for Antipsychotic-Induced Adverse Effects in Pediatric Population: Dearth of DataChild and Adolescent Psychopharmacology News, Vol. 21, No. 4Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders22 April 2016 | Australian & New Zealand Journal of Psychiatry, Vol. 50, No. 5Psychiatry Research, Vol. 237Diabètes iatrogènes : Importance d'une analyse critique du rapport bénéfices/risques des traitements en causeMédecine des Maladies Métaboliques, Vol. 9, No. 3Topiramate for Weight Loss in Two Young Adult Women with Autism Spectrum DisorderJournal of Child and Adolescent Psychopharmacology, Vol. 25, No. 2Acta Psychiatrica Scandinavica, Vol. 132, No. 2The use of clinical and biological characteristics to predict outcome following First Episode Psychosis27 November 2014 | Australian & New Zealand Journal of Psychiatry, Vol. 49, No. 1BJPsych Advances, Vol. 21, No. 6Double jeopardy: diabetes and severe mental illness. Addressing the special needs of this vulnerable groupDiabetes Management, Vol. 4, No. 4Adequate Dosing for Second-Generation Antipsychotics in Establishing Treatment Resistance in SchizophreniaJimmy Lee, M.B.B.S, M.Med., and Gary Remington, M.D., Ph.D.1 January 2014 | American Journal of Psychiatry, Vol. 171, No. 1Metformin and Alzheimer's Disease RiskJonathan E. Rosenfeld, M.D., Ph.D.1 January 2014 | American Journal of Psychiatry, Vol. 171, No. 1Response to RosenfeldL. Fredrik Jarskog, M.D., and T. Scott Stroup, M.D., M.P.H.1 January 2014 | American Journal of Psychiatry, Vol. 171, No. 1 Volume 170Issue 9 September 2013Pages 947-952 Metrics PDF download History Published online 1 September 2013 Published in print 1 September 2013
Referência(s)